Table 1 Baseline characteristics and demographics
Characteristic | Disease stage | Total patient population (n) | ||
|---|---|---|---|---|
ND (n = 1599) | HD (n = 1408) | PD (n = 336) | ||
Age, years | 72.02 ± 12.78 | 65.76 ± 12.64 | 62.63 ± 13.50 | 3345 |
Male, n (%) | 875 (54.72) | 866 (61.50) | 216 (64.28) | 3345 |
Primary diagnosis, n (%) | ||||
Chronic glomerulonephritis | 390 (24.39) | 524 (37.21) | 113 (33.63) | 1027 |
Diabetic nephropathy | 551 (34.45) | 529 (37.57) | 123 (36.60) | 1205 |
Nephrosclerosis | 417 (26.07) | 158 (11.22) | 47 (13.98) | 622 |
Other | 240 (15.00) | 197 (13.99) | 53 (15.77) | 490 |
Previous ESA therapy, n (%) | ||||
Any | 809 (50.59) | 1284 (91.19) | 263 (78.27) | 2357 |
Erythropoietin | 286 (17.88) | 664 (47.15) | 32 (9.52) | 982 |
Darbepoetin α | 523 (32.70) | 620 (44.03) | 231 (68.75) | 1375 |
Duration of dialysis, years | – | 6.78 ± 7.06 | 2.18 ± 2.47 | |
Hb, g/dL | 9.68 ± 1.12 | 10.27 ± 1.18 | 10.15 ± 1.28 | 3191 |
eGFR, mL/min/1.73 m2 | 18.55 ± 11.82 | – | 5.56 ± 2.81 | |
Serum creatinine, mg/dL | 3.43 ± 2.12 | – | 9.21 ± 3.32 | |
Albumin, g/dL | 3.66 ± 0.55 | 3.65 ± 0.42 | 3.29 ± 0.49 | 2837 |
Ferritin, ng/mL | 162.75 ± 188.51 | 144.38 ± 179.77 | 159.45 ± 126.12 | 1636 |
TSAT, % | 28.91 ± 13.20 | 25.38 ± 11.72 | 34.54 ± 13.34 | 1508 |